benzinga.com
/1 month ago
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
Revolution Medicines stock rises after Phase 3 daraxonrasib data show survival gains in pancreatic cancer, with regulatory filings planned. Importance Rank: ...